Ji Hoon Oh
Overview
Explore the profile of Ji Hoon Oh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
399
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kim C, Kim Y, Oh J, Kim M
Anticancer Res
. 2021 Jul;
41(7):3409-3417.
PMID: 34230136
Background/aim: ER-positive breast cancer patients commonly undergo endocrine therapy with drugs such as tamoxifen. Despite tamoxifen being a highly effective drug, long-term treatment results in resistance in one-third of the...
12.
Kim Y, Kim C, Oh J, Kim M
Cells
. 2021 Jul;
10(7).
PMID: 34209871
Endocrine therapy is used to treat estrogen receptor (ER)-positive breast cancer. Tamoxifen is effective against this cancer subtype. Nonetheless, approximately 30% of patients treated with tamoxifen acquire resistance, resulting in...
13.
Kim C, Kim Y, Oh J, Kim M
J Cancer
. 2021 Jun;
12(15):4626-4637.
PMID: 34149926
Tamoxifen is a commonly used drug to treat estrogen receptor-positive patients with breast cancer. Despite the outstanding efficacy of tamoxifen, approximately one-third of patients develop resistance toward it, thereby presenting...
14.
Jung J, Lee H, Song M, Hwangbo A, Beom J, Lee S, et al.
J Nat Prod
. 2021 Mar;
84(4):1422.
PMID: 33761258
No abstract available.
15.
Park S, Oh J, Park D, Zhang H, Noh M, Kim Y, et al.
Front Immunol
. 2021 Feb;
11:620166.
PMID: 33584714
Blocking the immune evasion mechanism of tumor cells has become an attractive means for treating cancers. However, the usage of a drug such as nivolumab (αPD-1), which blocks programmed cell...
16.
Jung J, Lee H, Song M, Hwangbo A, Beom J, Lee S, et al.
J Nat Prod
. 2021 Feb;
84(2):195-203.
PMID: 33534559
Separating the immunosuppressive activity of FK506 () from its neurotrophic activity is required to develop FK506 analogues as drugs for the treatment of neuronal diseases. Two new FK506 analogues, 9-deoxo-36,37-dihydro-prolylFK506...
17.
Stacy A, Andrade-Oliveira V, McCulloch J, Hild B, Oh J, Perez-Chaparro P, et al.
Cell
. 2021 Jan;
184(3):615-627.e17.
PMID: 33453153
The microbiota shields the host against infections in a process known as colonization resistance. How infections themselves shape this fundamental process remains largely unknown. Here, we show that gut microbiota...
18.
Oh J, Lee J, Kim K, Kim C, Jeong D, Cho Y, et al.
Cancer Lett
. 2020 Sep;
495:145-155.
PMID: 32987137
Approximately 70% of breast cancers are estrogen receptor (ER)-positive and treated with endocrine therapy. A commonly used treatment agent, tamoxifen, shows high efficacy for improving prognosis. However, approximately one-third of...
19.
Seong D, Jeong M, Seo J, Lee J, Hwang C, Shin H, et al.
Proc Natl Acad Sci U S A
. 2020 Aug;
117(33):19982-19993.
PMID: 32753382
The underlying mechanism of necroptosis in relation to cancer is still unclear. Here, MYC, a potent oncogene, is an antinecroptotic factor that directly suppresses the formation of the RIPK1-RIPK3 complex....
20.
Kim C, Oh J, Lee J, Kim M
J Cancer
. 2020 Apr;
11(12):3416-3423.
PMID: 32284737
Breast cancer is one of the most commonly diagnosed cancers in women worldwide. Approximately 40% of patients with breast cancer acquire endocrine resistance following therapy with tamoxifen. Many explanations for...